TY - JOUR
T1 - Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices
T2 - Lack of harmonisation and guidelines
AU - Illamola, Sílvia M.
AU - Hirt, Déborah
AU - Tréluyer, Jean M.
AU - Urien, Saik
AU - Benaboud, Sihem
N1 - Publisher Copyright:
© 2014 Elsevier Ltd. All rights reserved.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - The unbound drug concentration in plasma is usually considered the only active fraction; thus the binding of a drug to a protein limits its pharmacological actions. This is of special importance for those highly bound drugs. Therefore, binding studies can be of great utility for those drugs where relationship between free and total drug concentration is variable among patients, or it can be altered by some condition or disease, or even by interactions with other drugs. However, there is a lack of validation guidelines for the determination of unbound concentrations. Antiretroviral drugs (ARVs), protease inhibitors (PIs), efavirenz and nevirapine are highly bound to proteins. Here, we present a review on the overall methods for the study of unbound fractions of highly bound plasma protein ARVs. We also provide a critical evaluation of the methods applied, their differences and the main points to be controlled and validated.
AB - The unbound drug concentration in plasma is usually considered the only active fraction; thus the binding of a drug to a protein limits its pharmacological actions. This is of special importance for those highly bound drugs. Therefore, binding studies can be of great utility for those drugs where relationship between free and total drug concentration is variable among patients, or it can be altered by some condition or disease, or even by interactions with other drugs. However, there is a lack of validation guidelines for the determination of unbound concentrations. Antiretroviral drugs (ARVs), protease inhibitors (PIs), efavirenz and nevirapine are highly bound to proteins. Here, we present a review on the overall methods for the study of unbound fractions of highly bound plasma protein ARVs. We also provide a critical evaluation of the methods applied, their differences and the main points to be controlled and validated.
UR - http://www.scopus.com/inward/record.url?scp=84939959565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939959565&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2014.11.010
DO - 10.1016/j.drudis.2014.11.010
M3 - Review article
C2 - 25463032
AN - SCOPUS:84939959565
SN - 1359-6446
VL - 20
SP - 466
EP - 474
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 4
ER -